All In Biotech

Drug Trial Radar · NCT06881264

A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

A Randomized, Open-label, Parallel, Treat to Target Study Comparing the Efficacy and Safety of HR17031 With Insulin Glargine in Chines Subjects With Type 2 Diabetes Inadequately Controlled With Metformin in Combination With or Without Another Oral Antidiabetic Drug (OAD)

Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 401 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

401

Actual

Start

Apr 30, 2024

Primary completion

Sep 19, 2025

Study completion Sep 19, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this trial is to confirm the efficacy of HR17031 in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents

Conditions

  • Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs

Interventions

  • HR17031 injectionDrug

    HR17031 injection

  • insulin glargineDrug

    insulin glargine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c: Changes in HbA1c from baseline to week 26Time frame: week 26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.